ATF5 and glioblastoma: Noticeably, 33%of mice receiving ATF5-CaP-rHDL were able to survive more than 100 days.Likewise, in the GICs glioblastoma models (Fig. 9e), themean survival of those animals administered with saline, NC-CaP-rHDL,ATF5-CaP-LNC and ATF5-CaP-rHDL were 25, 26, 25 and 40 days, respectively.Collectively, these in vivo antitumor studies provided evidence tosupport our hypothesis that CaP-rHDL not only efficiently delivers siRNA to thetarget tissue, but also facilitates the gene knockdown activity to exert itsantitumor efficacy.